Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

13.60
+0.81506.38%
Post-market: 13.52-0.0750-0.55%19:51 EDT
Volume:4.12M
Turnover:54.96M
Market Cap:1.41B
PE:-2.61
High:13.71
Open:12.82
Low:12.73
Close:12.78
Loading ...

Stock Track | Intellia Therapeutics Soars 5.49% Pre-market on Strong Q1 Results and Extended Cash Runway

Stock Track
·
08 May

Intellia Therapeutics Ended Q1 2025 With Approximately $707.1M In Cash, Cash Equivalents And Marketable Securities; Expected To Fund Operations Into 1H Of 2027

Benzinga
·
08 May

Intellia Therapeutics Q1 2025 EPS $(1.10) Beats $(1.27) Estimate, Sales $16.63M Beat $11.87M Estimate

Benzinga
·
08 May

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks
·
05 May

Director Muna Bhanji Reports Disposal of Common Shares of Intellia Therapeutics Inc

Reuters
·
02 May

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Zacks
·
01 May

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Dow Jones
·
22 Apr

Intellia Therapeutics Raised to Outperform From Peer Perform by Wolfe Research

Dow Jones
·
22 Apr

Intellia Therapeutics Shares Rise After Upgrade From Wolfe Research

MT Newswires Live
·
22 Apr

Intellia Therapeutics upgraded at Wolfe on sentiment, valuation

TIPRANKS
·
21 Apr

Wolfe Research Upgrades Intellia Therapeutics to Outperform From Peer Perform, Price Target is $21

MT Newswires Live
·
21 Apr

Intellia Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research

TIPRANKS
·
21 Apr

NTLA Lawsuit Alert! Class Action Lawsuit Against Intellia Therapeutics Inc.

TIPRANKS
·
14 Apr

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

Insider Monkey
·
09 Apr

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Apr

Intellia Therapeutics announces first patient dosed in MAGNITUDE-2 trial

TIPRANKS
·
03 Apr

BRIEF-Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy

Reuters
·
03 Apr

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

GlobeNewswire
·
03 Apr

RBC Cuts Price Target on Intellia Therapeutics to $32 From $37, Keeps Outperform, Speculative Risk

MT Newswires Live
·
03 Apr

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?

Insider Monkey
·
02 Apr